<DOC>
	<DOCNO>NCT00089128</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine irinotecan , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together irinotecan work treat patient locally advance metastatic bladder cancer .</brief_summary>
	<brief_title>Gemcitabine Irinotecan Treating Patients With Locally Advanced Metastatic Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response patient locally advance metastatic transitional cell carcinoma bladder treat gemcitabine irinotecan . Secondary - Determine duration response patient treat regimen . - Determine tolerance toxicity regimen patient . - Determine median progression-free survival patient treat regimen . OUTLINE : Patients receive gemcitabine IV 30 minute irinotecan IV 90 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients respond disease receive 2 additional course beyond best response . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 25 patient accrue study within 24 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma bladder Locally advance metastatic disease Unidimensionally measurable disease physical exam image study The following consider measurable disease : Bone disease Pleural peritoneal effusion CNS lesion Irradiated lesion unless disease progression document radiotherapy Not amenable surgery PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL Renal Creatinine ≤ 2.0 mg/dL Gastrointestinal No active inflammatory bowel disease No significant bowel obstruction No chronic diarrhea Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active malignancy except nonmelanoma skin cancer No mental incapacitation psychiatric illness would preclude give informed consent No severe disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy No 1 prior platinumbased chemotherapy regimen At least 4 week since prior chemotherapy No prior irinotecan gemcitabine No concurrent chemotherapy Endocrine therapy No concurrent hormone except steroid adrenal failure , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent dexamethasone antiemetic Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy No concurrent palliative radiotherapy Surgery Not specify Other No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
</DOC>